Abstracts

Omuro, A. M. P., et. al. Phase IB trial of carboxyamidotriazole orotate (CTO) and radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ) in newly diagnosed glioblastoma (GBM). J.Clin Oncol 34, 2016 (suppl; Abstract 2060).

Lin, X., et. al. Phase IB trial of carboxyamidotriazole orotate (CTO) combined with temozolomide (TMZ) for recurrent glioblastoma (GBM) and other malignant gliomas (MG). J. Clin Oncol 34, 2016 (suppl; Abstract 2064).

Thomas, A., et al. Phase IB trial of CTO and radiotherapy with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma. J. Clin Oncol 33, 2015 (suppl; Abstract 2062)

Omuro, A. M. P., et. Al. Phase IB Trial of Carboxyamidotriazole Orotate (CTO) and Temozolomide for Recurrent Malignant Glioma (MG): A Novel Mechanism for Modulation of Multiple Oncogenic pathways. J. Clin Oncol 32, 2014 (suppl; Abstract 2071)

Magge, R., et al. Dynamic contrast-enhanced magnetic resonance perfusion weighted imaging (DCE-MRI) and diffusion weighted imaging (DWI) for pharmacodynamic evaluation of CTO and temozolomide in malignant glioma. Society of Neuro-oncology, 2014. Abstract.

Sandler, A., et. Al. A Phase I Study of Carboxyamidotriazole Orotate (CTO) in Treatment of Advanced Solid Tumors. J. Clin Oncol xx, 2013 (suppl; Abstract 2518).

Karmali R, Miele, G., editor, Pharmacodynamic Transcriptional markers of carboxyamidotriazole orotate (CTO) exposure in anagen hair. Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 19-23 October, Abs. 367; Boston MA.